Upside – $CNTB +83% (Phase 2 COPD trial met its primary endpoint, reducing treatment failures by 81% and new moderate-to-severe exacerbations by 85%) – $NAUT +16% (no clear fresh catalyst identified; unusually large, liquid premarket move) – $CAPR +14% (new deramiocel analyses showed slower upper-limb decline in the HOPE-3 open-label extension and versus natural history) …
Read in context ›Sagimet Biosciences, Inc. Class A Stock (SGMT)
Track Sagimet Biosciences, Inc. Class A stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
SGMT
Sagimet Biosciences, Inc. Class A
healthcare
At close
$8.93
â–² +0.01 (+0.11%)
Oct 9, 4:00 PM ET
After-hours
$8.90
â–¼ -0.03 (-0.34%)
Oct 9, 7:30 PM ET
Market Cap
$627.44M
P/E Ratio
—
1Y Return
+3.60%
EPS (TTM)
-$1.28
Read the latest TheStreet Pro articles mentioning Sagimet Biosciences, Inc. Class A, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning SGMT yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning